BG
Bellevue Group Portfolio holdings
AUM
$4.54B
This Quarter Return
-1.98%
1 Year Return
+22.5%
3 Year Return
+98.22%
5 Year Return
+159.37%
10 Year Return
–
AUM
$4.46B
AUM Growth
+$4.46B
(-14%)
Cap. Flow
-$467M
Cap. Flow
% of AUM
-10.47%
Top 10 Holdings %
Top 10 Hldgs %
48.58%
Holding
170
New
10
Increased
26
Reduced
81
Closed
22
Top Buys
| 1 |
Akero Therapeutics
AKRO
|
$50.6M |
| 2 |
AbbVie
ABBV
|
$18.9M |
| 3 |
Stryker
SYK
|
$17.3M |
| 4 |
Beam Therapeutics
BEAM
|
$17.1M |
| 5 |
Baxter International
BAX
|
$15.6M |
Top Sells
| 1 |
ITCI
Intra-Cellular Therapies Inc.
ITCI
|
$204M |
| 2 |
Arvinas
ARVN
|
$45.8M |
| 3 |
Vertex Pharmaceuticals
VRTX
|
$36.1M |
| 4 |
VRNA
Verona Pharma
VRNA
|
$32.2M |
| 5 |
Tandem Diabetes Care
TNDM
|
$28.2M |
Sector Composition
| 1 | Healthcare | 99.87% |
| 2 | Technology | 0.01% |
| 3 | Communication Services | 0.01% |
| 4 | Consumer Discretionary | 0% |
| 5 | Consumer Staples | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
126
ADMA Biologics
ADMA
$4.12B
| $335K | 0.01% |
16,900
| – | – |
|
127
Exelixis
EXEL
$10.1B
| $314K | 0.01% |
+8,500
| New | +$314K |
|
128
Ascendis Pharma
ASND
$11.8B
| $296K | 0.01% |
1,900
-600
| -24% | -$93.5K |
|
129
Oculis Holding
OCS
$844M
| $268K | 0.01% |
14,100
+4,100
| +41% | +$78K |
|
130
Mineralys Therapeutics
MLYS
$1.03B
| $262K | 0.01% |
16,499
| – | – |
|
131
uniQure
QURE
$896M
| $239K | 0.01% |
22,500
| – | – |
|
132
Arcellx
ACLX
$3.85B
| $197K | ﹤0.01% |
3,000
| – | – |
|
133
PTC Therapeutics
PTCT
$3.92B
| $194K | ﹤0.01% |
3,800
| – | – |
|
134
Garmin
GRMN
$46.5B
| $185K | ﹤0.01% |
850
-200
| -19% | -$43.4K |
|
135
Baidu
BIDU
$32.8B
| $184K | ﹤0.01% |
2,000
| – | – |
|
136
Amazon
AMZN
$2.44T
| $171K | ﹤0.01% |
+900
| New | +$171K |
|
137
Alphabet (Google) Class A
GOOGL
$2.57T
| $170K | ﹤0.01% |
+1,100
| New | +$170K |
|
138
Cytokinetics
CYTK
$4.23B
| $150K | ﹤0.01% |
3,741
-7,200
| -66% | -$289K |
|
139
MoonLake Immunotherapeutics
MLTX
$3.54B
| $117K | ﹤0.01% |
3,000
-1,400
| -32% | -$54.7K |
|
140
BellRing Brands
BRBR
$5.17B
| $104K | ﹤0.01% |
+1,400
| New | +$104K |
|
141
Agilent Technologies
A
$35.7B
| $94.3K | ﹤0.01% |
806
| – | – |
|
142
Oracle
ORCL
$635B
| $91.4K | ﹤0.01% |
654
| – | – |
|
143
NVIDIA
NVDA
$4.24T
| $81.4K | ﹤0.01% |
751
| – | – |
|
144
Microsoft
MSFT
$3.77T
| $76.2K | ﹤0.01% |
203
| – | – |
|
145
Qualcomm
QCOM
$173B
| $68.7K | ﹤0.01% |
447
| – | – |
|
146
Biogen
BIIB
$19.4B
| $55K | ﹤0.01% |
402
-2,250
| -85% | -$308K |
|
147
Mettler-Toledo International
MTD
$26.8B
| $49.6K | ﹤0.01% |
42
| – | – |
|
|
TEM
148
Tempus AI, Inc. Class A Common Stock
TEM
$13.2B
| $11.4K | ﹤0.01% |
237
| – | – |
|
149
Amneal Pharmaceuticals
AMRX
$3B
| – | – |
-100,414
| Closed | -$795K |
|
|
150
Arvinas
ARVN
$568M
| – | – |
-2,389,600
| Closed | -$45.8M |
|